• Home:
  • News:
  • INC Research Named Best Contract Research Organization at 11th Annual Scrip Awards

News

12/3/2015 INC Research Named Best Contract Research Organization at 11th Annual Scrip Awards

Raleigh, N.C., Dec. 3, 2015 – INC Research Holdings, Inc. (INC Research)(Nasdaq: INCR), a leading, global Phase I to IV contract research organization, today announced the Company was named  “Best Contract Research Organization” at the 11th Annual Scrip Awards held Dec. 2 in London. INC was selected from among several leading global CROs by a distinguished panel of life science industry executives. The “Best CRO” ranking from Scrip follows INC Research’s recognition earlier in the year as “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.

“INC Research employees are passionate about bringing new medicines to market to improve world health,” said Jamie Macdonald, Chief Executive Officer.  “Being named ‘Best CRO’ is a true testament to their hard work and dedication, and our ability to collaborate effectively with customers and sites worldwide in the development of ground-breaking new therapies that improve patient lives. To be selected from among such a distinguished group of peers is an incredible honor. INC’s focus will continue to be first and foremost on meeting our customers’ needs for innovative and forward-thinking clinical development solutions that achieve their vision and ultimately benefit patients.”

The annual Scrip awards competition, organized by Scrip Intelligence, the premier source of information for the global biopharmaceutical industry, is designed to celebrate the contributions of the pharmaceutical, biotech and other allied industries to improving human health worldwide. Recognizing that clinical outsourcing is vital to the pharmaceutical industry, SCRIP’s “Best CRO” Award acknowledges the critical role CROs play in drug development. 

“Our judges selected INC Research based on its impressive growth as one of the world’s leading CROs and its ability not only to keep up with the changing needs of the environment but its effort to be an agent in driving positive change in the clinical development process,” said Mike Ward, Global Director of Content for Informa Pharma and Healthcare. “The qualifying year was a milestone year for the Company, culminating in its initial public offering and its contribution to the development of a number of ground-breaking therapies. INC’s therapeutic focus, unique Trusted Process® clinical development methodology and significant commitment and progress in the development of strong site relationships really make it stand above our other nominations this year.”

About INC Research

INC Research (Nasdaq: INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.  Leveraging the breadth of our service 
offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.  The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.  INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries.  


Back to previous

© 2017 Avista Capital Partners.